Hims & Hers climbs on Novo Nordisk deal and peptide build-out
The telehealth firm is constructing a California peptide manufacturing site and plans a 2026 longevity line of peptides, coenzymes and GLP/GIP treatments.
TR
By Tom Reyes · Markets Editor
Apr 20 03:00 ETSource: 24/7 Wall St.
The wire
- 01Hims & Hers shares rose 9% Monday to about $31, a 49% gain over five sessions, ahead of a May 11 earnings report, on a Novo Nordisk distribution arrangement and renewed interest in peptide therapeutics.
- 02The company has built over 1 million square feet of US facility space including sterile injectable capacity, which would shift it from compounded GLP-1s toward branded Wegovy distribution and a peptide product line.
- 03Guidance is $600 million to $625 million in quarterly revenue, but analysts expect EPS of $0.06, a 70% year-over-year decline; deal terms and the peptide launch timing remain unconfirmed.
From the source
Read at 247wallst.comHims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal
Hims & Hers Health ( NYSE:HIMS ) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors pile into the stock ahead of a May 11 earnings report. The move caps a stunning week: HIMS stock has surged 49% in the past five trading sessions, making it one of the market’s most explosive movers heading into a quarterly print.